cardiovascular-agents has been researched along with dolutegravir* in 1 studies
1 other study(ies) available for cardiovascular-agents and dolutegravir
| Article | Year |
|---|---|
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
: The risk of drug-drug interactions (DDIs) is elevated in aging people living with HIV (PLWH) because of highly prevalent age-related comorbidities leading to more comedications. To investigate the impact of aging on DDI magnitudes between comedications (amlodipine, atorvastatin, rosuvastatin) and boosted darunavir, we conducted a clinical trial in aging PLWH aged at least 55 years. DDI magnitudes were comparable with those reported in young individuals supporting that the clinical management of DDIs in aging PLWH can be similar. Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome | 2020 |